Six Korean Bio Stocks, Made Simple — 'The Catalyst Is Alive' and 'It's Cheap' Are Not the Same Thing (2026-06-11)

Thu, 11 Jun 2026 10:30:00 +0900

🔗 Read together: Our earlier Korea bio-sector thesis — the market that rewards ‘under-priced data’ (must read) · PharmaResearch — the PDRN pioneer behind Rejuran · PharmaResearch re-rating check · The Real Money flow framework

Last time we set one principle: Korean bio is not a market that rewards “good technology,” but one that rewards “stocks where the good news is still under-priced.” This post applies that same rule to six flagship names — in plain language. Jargon is explained in parentheses.

First, remember just two words

Two words keep showing up in investing, and they are the whole point of this post.

Catalyst = the trigger that can lift a stock. A drug approval, a licensing deal, a profit surge — the kind of event where “if this lands, the stock moves.”
Undervalued = cheap. It means that trigger is still not fully priced in.

Here is the key. “The catalyst is alive” and “it’s cheap right now” are different statements. Even a great company is a tough new buy if the good news is already stuffed into the price. Conversely, an ordinary-looking name can be an opportunity if the good news is still under-priced.

TL;DR (3 lines)

For all six names the catalyst (trigger) is alive. None of them is dead.
But “alive ≠ cheap.” For fresh money today, the two worth accumulating are SK Biopharm and ST Pharm.
Samsung Biologics and Alteogen are great companies but already in expensive territory; Hanmi still needs launch proof; Oscotec is a “lottery-ticket” name that pays big if it works.

One-page summary

Company (ticker)	Catalyst alive?	Cheap now?	One-line call
SK Biopharm (326030)	Very strong	Yes	Already selling a drug and earning, yet near a 1-year low → #1
ST Pharm (237690)	Strong	Yes (conditional)	RNA-drug factory with orders piling up → #2
Hanmi (128940)	Strong	Not yet	Obesity-drug bet; wait for launch proof
Oscotec (039200)	Alive (revived)	Partial	Royalties hold the floor; new out-licensing is a “lottery” → high risk
Samsung Biologics (207940)	Alive	No	#1 contract manufacturer; great but already expensive
Alteogen (196170)	Strongest	No	Catalyst is strongest, but expectations are already loaded → cautious new buy

By catalyst strength alone, Alteogen ranks first. But once you also ask “is it cheap?”, the order flips completely. That flip is the whole point of this post.

The six, in plain terms

1. SK Biopharm — “a company that already sells a drug and makes money”

The easiest name to grasp. While other biotechs sell the dream of “someday, if a drug arrives…,” SK Biopharm already sells the epilepsy drug ‘Xcopri (cenobamate)’ in the US and earns from it.

Q1 revenue was about KRW 227.9bn (+57.8% YoY) and operating profit about KRW 89.8bn (+249.7%), a record quarter. Xcopri US sales alone were about KRW 197.7bn (+48.4%). Because the company built its own US sales force, profits now grow faster than sales as volume rises (operating leverage).

Cheap? On the morning of June 11 the stock was about KRW 84,000, just above its 1-year low (~KRW 81,000) and far from its 1-year high (~KRW 144,000). Profits are climbing fast yet the price sits near the bottom, so it is not expensive relative to its earnings growth. The market still discounts it as “a risky biotech reliant on a single product” — and that looks like the opportunity.

Risks: single-product reliance on Xcopri, slowing US prescription growth, cost of bringing in a second product.

Call: very strong catalyst + undervalued → #1 for fresh money (accumulate in tranches).

2. ST Pharm — “the RNA-drug factory with orders piling up”

ST Pharm does not bet on whether a trial succeeds. It is a contract maker (CDMO) of RNA/oligonucleotides (the core raw material of gene-based drugs). Whether the drug succeeds or not, it earns when orders to make that drug come in. It is closer to an industrial (a factory) than to a biotech.

The key now is that orders are piling up. Q1 operating profit was about KRW 11.5bn, up a massive +1,024% YoY, and the oligo order backlog (orders already booked) is about KRW 340bn–460bn (varies by source), of which over 80% is actual commercial volume, not clinical. In January it signed an oligo supply deal with a US pharma and in March one with a European pharma, each worth KRW 80bn–90bn. It also completed a second plant (Oligo Building 2) last September.

Cheap? On the June 11 morning the stock was about KRW 117,000 (1-year high ~KRW 172,000). On a simple trailing PER (~43x) it looks pricey, but that is an illusion. PER uses “past 12 months’ earnings”; as the backlog converts to revenue and profit through 2026–2027 and plant utilization rises, earnings grow quickly. Analysts see this year’s operating profit up +42% and call the share-price drop overdone.

Risks: undisclosed clients / order concentration, early plant fixed costs, quarter-to-quarter shipment timing.

Call: strong catalyst + conditional undervaluation → #2 for fresh money (accumulate in tranches).

3. Hanmi — “an obesity-drug bet; trust restored, but wait for launch proof”

Hanmi’s trigger is obesity / metabolic drugs. It recently out-licensed a candidate (sonefpeglutide) to global pharma Eli Lilly — total deal about USD 1.26bn, with a non-refundable upfront of USD 75m. A big company buying Hanmi’s technology signals restored trust in its R&D.

The next gate is Hanmi’s own obesity drugs. Its in-house obesity candidate (efpeglenatide) has filed for Korean approval, targeting a 2H 2026 domestic launch, while a next-generation candidate (HM15275, etc.) is in Phase 2.

Cheap? On the June 11 morning the stock was around KRW 390,000s (1-year high ~KRW 647,000). The pullback was large, but because the stock already rose once right after the June Lilly deal, calling this “the bottom” is early. The bigger issue: the obesity market is already crowded with strong players like Wegovy and Zepbound. A “homegrown GLP-1” story alone is not enough — actual approval, pricing and early prescription numbers must show up.

Call: strong catalyst + right after the event → wait for launch / data (Wait).

4. Oscotec — “royalties hold the floor; the new out-license is a lottery”

Think of Oscotec as having two engines. One is already paying — the lung-cancer drug ‘Leclaza (lazertinib)’ sells globally and brings in royalties, which support the floor under the stock. The other is a lottery engine — it out-licensed its candidate (cevidoplenib) to US-based Agios. Total deal up to USD 600m+, upfront USD 25m (Oscotec’s share about 75%).

One honest caveat: cevidoplenib failed to hit its primary endpoint statistically in Phase 2. Some secondary readouts were good and the partner is preparing the next step (Phase 3), but the Phase 3 entry target is 2028, so it is far out and failure risk remains.

Cheap? June 11 morning price about KRW 38,500 (1-year high ~KRW 66,000), market cap ~KRW 1.47tn. On earnings (PER) it is not a cheap stock. It is an option-type name where you buy the stable Leclaza royalty plus the cevidoplenib/new-pipeline lottery.

Call: catalyst alive but high risk → Watchlist; small size / diversify as a rule.

5. Samsung Biologics — “the #1 contract manufacturer; great but already expensive”

Samsung Biologics’ trigger is not a trial but factories. It is the #1 contract maker (CDMO) of biologics for the world’s drugmakers. Q1 revenue was about KRW 1.2571tn and operating profit about KRW 580.8bn, with Plants 1–4 at full run, Plant 5 starting up, the US (Rockville) plant acquisition (total capacity expanded to 845,000 liters), and a dedicated ADC (antibody-drug conjugate, a next-gen drug) facility — the growth fuel is clearly alive.

Cheap? This is the point. June 11 morning price about KRW 1.26m, market cap about KRW 58tn, PER ~28x. It is off its 1-year high (~KRW 1.98m), but this company is already valued as “a world-class, premium contract manufacturer.” So it is not “a cheap biotech” but “a good company that pulled back a little.” There is upside, but it is unlikely to re-rate as fast as a drug-approval winner.

Call: catalyst alive but not undervalued (premium) → buy on dips (Wait).

6. Alteogen — “the strongest catalyst, but expectations are already loaded”

Alteogen owns a platform (ALT-B4) that converts intravenous (IV) cancer drugs into subcutaneous (SC) injections. A shot that took hours in hospital becomes quick, so drugmakers line up. In fact the SC version of Merck (MSD)’s mega cancer drug ‘Keytruda’ won US FDA approval, with deals following from AstraZeneca, GSK, Biogen, Daiichi Sankyo, Sandoz and others. By catalyst strength, it is the strongest of the six.

Cheap? No. June 11 morning price about KRW 303,000, market cap about KRW 16tn, PER a striking ~120x. The expectation that “huge royalties are coming” is already loaded into the price. On top of that, a recent Merck disclosure showed the Keytruda SC royalty rate at around 2%, below the 4–5% the market hoped, trimming expectations. Patent litigation (the dispute with Halozyme) is another variable.

In short, Alteogen is not “cheap”; it is a stock that gets re-priced every time Keytruda SC sales and royalties show up in the numbers.

Call: strongest catalyst but already expensive → cautious new buy (wait for a price reset / royalty confirmation).

So what’s the priority?

Even with the same “catalyst alive,” once you also weigh “is it cheap?” the order shapes up like this.

Worth accumulating now (catalyst + undervalued): SK Biopharm, ST Pharm
R&D-hope type (after confirmation): Hanmi
Lottery type (high risk / high reward): Oscotec
Large, stable type (on dips): Samsung Biologics
Platform-hope type (already expensive): Alteogen

In one sentence: “A live catalyst and a cheap price are different things. The two that satisfy both are SK Biopharm and ST Pharm.”

Checkpoints that would change the call

If the numbers below change, the conclusions above change too. When the news drops, watch only these.

SK Biopharm: Xcopri US sales growth (holding 30%+ per quarter?), operating margin (defending 30%+?).
ST Pharm: Q2–Q3 oligo shipment normalization, backlog held/growing, rising plant utilization.
Hanmi: obesity-drug approval / pricing / early prescriptions; next-gen candidate (HM15275, etc.) data.
Oscotec: are Leclaza royalties growing each quarter; is the cevidoplenib Phase 3 schedule confirmed.
Samsung Biologics: Plant 5 revenue ramp, US (Rockville) contribution, pace of new large orders.
Alteogen: actual Keytruda SC conversion rate / quarterly royalty amount, direction of the patent suit.

The bottom line

Among these six, no catalyst (trigger) is dead. The issue, as always, is price. You don’t buy a good company at any price — you pick the name where the good news is still under-priced. That principle from our last bio post applies again here. On today’s read, the two that best meet that test are SK Biopharm and ST Pharm.

FAQ

Q. The catalyst is “alive,” so why not buy? A. Even with a live trigger, if the good news is already fully in the price, there is little left for a new buyer. That is Alteogen and Samsung Biologics. A good company is not the same as a cheap stock.

Q. So will SK Biopharm and ST Pharm definitely rise? A. No. It means they are “more attractive on catalyst-vs-price than the other four,” not a guarantee. SK Biopharm carries single-product (Xcopri) reliance and ST Pharm has quarterly shipment swings. That is why the rule is to buy in tranches, not all at once.

Q. ST Pharm is at PER 43x — how is that cheap? A. PER uses “last 12 months’ earnings,” which creates an illusion. ST Pharm is at the start of converting its backlog into revenue and profit, so on forward earnings it may not be as expensive as today’s PER.

Q. Why is Oscotec a “lottery”? A. The Leclaza royalty is stable, but the out-licensed cevidoplenib missed its Phase 2 primary endpoint and its next step is in 2028. The payoff is big if it works, but failure risk is high — hence small size and diversification.

Q. Is this a buy recommendation? A. No. It is not individual buy/sell advice but a research lens that separates “catalyst alive” from “undervalued.” Invest on your own judgment and responsibility.

이 글은 리서치·정보 제공용이며 투자 조언이 아닙니다. 종목명은 분석을 위한 예시이며, 매수·매도 권유가 아닙니다. 본문의 주가·시가총액·PER은 2026년 6월 11일 오전 장중 공개 시세 기준이고, 실적·계약 수치는 각사 공시·보도자료 기준입니다. 같은 항목이라도 집계 기준·시점에 따라 값이 다를 수 있어 일부는 범위로 표기했습니다. 데이터 기준일: 2026년 6월 11일 KST.

Disclaimer: For research and information purposes only. Not investment advice. Company names are cited for analytical illustration; readers should perform their own due diligence and consult licensed advisors before any investment decision. Prices, market caps and P/E ratios are intraday quotes as of June 11, 2026 (KST); financial and deal figures are based on company filings and press releases and may vary by source and timing.

Hanmi on Korea Invest Insights